Abstract: A human anti-cancer vaccine is prepared by culturing human cancer cells, such as human melanoma cells, human lung cancer cells, human colon cancer cells, human breast cancer cells, and other human cancer cells in a serum-free medium. The cells are selected on the basis of expressing different patterns of cell surface tumor antigens and are adapted to and are grown in a serum-free medium. During culturing antigens of the cancer cells are shed into the culture medium. The culture medium, containing the shed cancer cell antigens, is then concentrated, such as by vacuum ultrafiltration. In some instances the vaccine is then treated with a non-ionic surfactant or detergent, such as Nonidet P-40 (NP-40), to break up aggregates and treated with a presevative, such as sodium azide, and then subjected to ultracentrifugation.
Abstract: A stabilized aqueous adjuvant suspension of dimethyl dioctadecyl ammonium bromide stabilized with at least 0.1 part by weight of a polymer of acrylic acid crosslinked with polyallyl sucrose per part by weight of dimethyl dioctadecyl ammonium bromide, plusa method of stabilizing vaccines adjuvanted with such dimethyl dioctadecyl ammonium bromide.
Type:
Grant
Filed:
December 17, 1987
Date of Patent:
June 25, 1991
Assignee:
Duphar International Research B.V.
Inventors:
Lucas A. T. Hilgers, Marinus W. Weststrate
Abstract: A monoclonal antibody against human cancer, characterized in that the monoclonal antibody is produced by a hybridoma cell line obtained from the fusion of B-lymphocyte immunized with cells of human cancer origin and tumor cells, and reactive with cancer cells from more than one organ but substantially not reactive with normal cells, and a process for production thereof; and a hybridoma cell line used to produce the above-mentioned monoclonal antibody, and a process for production thereof.
Abstract: A hybrid cell line is developed which produces a monoclonal antibody which binds to a unique antigenic site expressed on the surface of phagocytic cells. The monoclonal antibody binds to and activates a specific domain of the CD11b glycoprotein so as to inhibit adhesion dependent functions of the phagocytic cell, but it does not affect other phagocytic functions. This monoclonal antibody can be used as a reactant in an in vitro diagnostic immunoassay for detecting the unique antigenic site on the surface of normal human neutrophils.
Abstract: A method and therapeutic composition for the treatment of bleeding disorders, for example those characterized by a tendency toward hemorrhage or a hypercoagulative state, by the administration of tissue factor protein or antagonists thereof.
Abstract: The invention concerns a novel lymphocyte hybridoma and an antibody which may be generated from the hybridoma. The hybridoma and antibody have the internal designation LICR-LON-Fib 75. The origin, method of preparation and uses are discussed. The antibody has particular application in the diagnosis and treatment of cancer of the breast. A particular therapeutic treatment comprises harvesting a sample of bone marrow from a patient, subjecting the patient to treatment adapted to kill cancerous material including that within the bone marrow (possibly including the normal differentiated haemopoietic cells of the marrow), subjecting some or all of the sample to cytotoxic treatment with the antibody (or a toxin conjugate thereof) adapted to kill cancerous cell lines while leaving viable colony-forming units of bone marrow, and reintroducing the treated sample material to the blood stream of the patient.
Type:
Grant
Filed:
December 23, 1987
Date of Patent:
March 26, 1991
Assignee:
Ludwig Institute for Cancer Research
Inventors:
Alexander M. Neville, Christopher S. Foster, Paul A. W. Edwards, Robert A. J. McIlhinney
Abstract: Disclosed herein is a method for transforming human B-cells by infecting them with Epstein Barr virus and transfecting the Epstein Barr virus infected cells with an activated human c-myc gene. The transformed cells are useful for producing human monoclonal antibodies.
Abstract: Composition for the prevention and treatment of autoimmune diseases are provided which comprise as an active ingredient membrane material shed from autoimmune T lymphocytes, or activated T lymphocytes which are treated by a pressure application and releases process. There is also provided processes for obtaining such active materials and for preparing pharmaceutical compositions containing them.
Abstract: The invention relates to antigenic preparations useful for inducing the production of antibodies in an individual which will bind to epitopes on zona pellucida. Also disclosed are immunogenic compositions and methods for immunizing an individual to enable the production of antibodies to zona pellucida antigens. Also disclosed are the use of these recombinant molecules and monoclonal antibodies thereto for immunocontraception or sterilization.
Abstract: Substantially pure cromolyn binding protein is prepared by means of affinity chromatography of cromolyn derivatives bound to insoluble matrices. Aminocromolyn is prepared by a six-step synthesis and amine derivatives thereof are prepared by conventional means. Obtaining a compound having an amine group instead of the OH group at the 2-carbon of the propane link of cromolyn permits many kinds of reactions without interfering with the portion of the cromolyn molecule with causes its pharmacological activity. The cromolyn derivatives can be conjugated to proteins such as BSA by means of glutaraldehyde cross-linking and such conjugates can be covalently bound to agarose beads. Cromolyn binding protein can be isolated by passing lysates of RBL-2H3 cells through chromatographic columns packed with such beads. The cromolyn binding protein can be further purified by means of lectin-agarose columns.
Abstract: Purified cytotoxic proteins for use within therapeutic compositions are disclosed. The proteins inhibit protein synthesis in vitro, exhibit abortifacient activity in mice, and contain proline residues with equivalent positions at residue 43 and residue 46 in ricin A-chain. A method for preparing such a cytotoxic protein from the tissue of Trichosanthes kirilowii is also disclosed. The proteins may also be used within a method for inhibiting protein synthesis in selected cells.
Type:
Grant
Filed:
April 10, 1987
Date of Patent:
January 15, 1991
Assignee:
ZymoGenetics, Inc.
Inventors:
John M. Maraganore, Wayne R. Kindsvogel
Abstract: New fragments of the Factor VIII procoagulant protein (Factor VIIIC) are disclosed. These fragments have an Mr value of 88,000 d or 49,000 d or extend from amino acid residues 1974 to 2332 or 2052 to 2332. These fragments have use in the treatment of patients who have developed antibodies which inhibit Factor VIII.
Type:
Grant
Filed:
April 6, 1987
Date of Patent:
December 25, 1990
Assignees:
Scripps Clinic and Research Foundation, Rorer Biotechnology Inc.
Inventors:
Dorothea H. Scandella, William N. Drohan, Theodore S. Zimmerman, Carol A. Fulcher
Abstract: The monoclonal antibodies are specific for a determinant found on hepatitis B surface antigen, and show high affinity for this determinant. Hybridomally produced monoclonal IgM antibodies having high affinity are useful for the immunoassay and purification of viral antigens.
Type:
Grant
Filed:
June 3, 1988
Date of Patent:
November 27, 1990
Assignee:
Massachusetts General Hospital
Inventors:
Jack R. Wands, Vincent R. Zurawski, Jr., Hubert J. P. Schoemaker
Abstract: The present invention is directed to in vitro and in vivo immunodiagnosis and immunotherapy using monoclonal antibodies reactive with difucosyl blood group antigens Y-6 and B-7-2.
Abstract: DTH-Effector cells are primed with carbohydrate antigens and used to enhance the cellular immune response. Tumors have been inhibited by DTH-Effector cells primed with epiglycanin and with synthetic T and Tn antigens. Either the DTH-Effector cells, or these tumor-associated carbohydrate antigens directly, may be used for tumor prophylaxis and therapy.
Type:
Grant
Filed:
July 21, 1988
Date of Patent:
November 20, 1990
Assignee:
Biomira, Inc.
Inventors:
B. Michael Longenecker, Carina Henningsson
Abstract: Antibodies are produced by hyperimmunizing a mammal, such as cow, with a vaccine derived from E. coli bacteria. The bacterial strains in the vaccine are selected on the basis of their virulence characteristics, especially adhesion factors (pili), associated with gastroenteric disease in humans. The antibodies can be recovered from the mammal's milk or serum, and used in human foods.
Type:
Grant
Filed:
November 19, 1986
Date of Patent:
November 20, 1990
Assignee:
Unilever Patent Holdings B.V.
Inventors:
Margaret A. Linggood, Philip Porter, Jonathan R. Powell
Abstract: A method of treating a hemoglobinopathic condition such as sickle cell anemia, by pulse treatment with erythropoietin. In one embodiment, each of one or more treatment regimens includes a first time period during which erythropoietin is administered to a hemoglobinopathic patient and a second time period during which erythropoietin is withheld from the patient. During the first time period, sufficient erythropoietin is administered to increase F-reticulocyte formation in the patient. The pulse treatment preferably includes a plurality of the treatment regimens, in which case the durations of the second time periods are selected to achieve a cumulative increment of F-cell count sufficient to effectively treat the patient'This invention was made partly with government support under one or more of grants HL20899 and HL21676 from the National Institutes of Health. The government has certain rights in this invention.
Type:
Grant
Filed:
April 3, 1987
Date of Patent:
October 23, 1990
Assignee:
The Board of Regents of The University of Washington
Abstract: Novel cell lines produce monoclonal antibody to the light chain region of human factor XII. Three such cell lines, ATCC #HB-9703 through ATCC #HB-9704, are formed by fusing SP2/0-Ag14 myeloma cells with spleen cells from BALB/c AnSkh mice immunized with human factor XIIf. Biochemical and therapeutic uses of the monoclonal antibodies are provided.
Type:
Grant
Filed:
June 9, 1988
Date of Patent:
October 16, 1990
Assignee:
Temple University of the Commonwealth System of Higher Education
Abstract: A substantially pure antigen found on normal and benign breast epithelial cell membranes and in breast cancer cells, fused cell hybrids which produce antibodies specific for such antigen, the monoclonal antibodies produced by such fused cell hybrids, a method for detecting the presence of breast cancer in a patient which is based on measuring the concentrations of one or more determinants of such antigen in a patient sample, and a method for either identifying those breast cancer patients whose tumors would respond to estrogen manipulation or determining prognosis based on the degree of differentiation, which method is based on measuring the concentration of an estrogen-modulated determinant of such antigen.
Type:
Grant
Filed:
December 28, 1988
Date of Patent:
October 2, 1990
Assignee:
Ciba Corning Diagnostics Corp.
Inventors:
Michael A. Harvey, Brenda D. Manning, Mary L. Nicholson, Karen L. Travis, Albert A. Luderer
Abstract: A prostate antigen distinct from prostatic acid phosphatase has been detected in normal, benign hypertrophic and malignant prostatic tissues, but not in other human tissues. The prostate antigen was purified to homogeneity from prostatic tissues by ammonium sulfate precipitation, DEAE-BioGel A anion exchange chromatography, molecular sievings on Sephadex G-100 and Sephadex G-75,This invention was supported in part by Grants No. CA-15126 and CA-15437 from the National Cancer Institute, U.S. Public Health Service.
Type:
Grant
Filed:
October 4, 1988
Date of Patent:
October 23, 1990
Assignee:
Research Corporation Technologies, Inc.
Inventors:
Tsann M. Chu, Ming C. Wang, Lawrence Papsidero